
Next stage of AI revolution arrives
Wall Street Breakfast
00:00
ScholarRock Faces FDA Complete Response Letter
Kim Kahn explains ScholarRock's FDA setback for epitogromab and implications for its SMA treatment approval path.
Play episode from 01:46
Transcript


